智通财经APP讯,宜明昂科-B(01541)公布,IMC-003/IMM72第一期临床试验的首名患者已成功给药,标志着集团IMC-003/IMM72临床研究的重大里程碑,并为促进随后临床试验奠定稳健基础。
据悉,IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型(ActRIIA-Fc)融合蛋白,具有更高的活性及品质。该集团拥有IMC-003/IMM72的全球知识产权以及开发及商业化权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.